Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

8,743 38,240 46,983

Oncology 23,949 47,642 71,591 8,743 38,240 46,983

Other 26,644 82,517 109,161 25,833 75,863 101,696

$727,480 $191,459 $918,939 $696,685 $162,388 $859,073

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 7% 26% 8%

GABITRIL (5%) (20%) (8%)

CNS 6% 18% 7%

ACTIQ (32%) 41% (21%)

Generic OTFC (13%) - (13%)

FENTORA 11% - 11%

AMRIX 100% - 100%

Pain (4%) 41% (1%)

TREANDA 100% - 100%

Other 9% 25% 22%

Oncology 174% 25% 52%

Other 3% 9% 7%

4% 18% 7%

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

June 30, December 31,

2008 2007

CURRENT ASSETS:

<
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering ... the Orange County, Texas area from future storm surge flooding, such as occurred in ... potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
(Date:7/28/2015)... 2015 People with a common form of ... and sometimes profound improvements in their hearing and understanding ... a new multicenter study led by specialists at NYU ... online ahead of print in the journal The Laryngoscope July ... in the United States implanted ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Inc. (OTCBB: GOVX), a biotechnology company that creates, ... its 2010 Annual Report and President,s Letter to ... information on the state of the Company,s finances ... GeoVax,s President Robert T. McNally, Ph.D., provides a ...
... Calif., May 4, 2011 Pharmacyclics, Inc. (Nasdaq: ... results for its fiscal third quarter that ended March ... Broad Clinical Development Progress for Btk Inhibitor PCI-32765 in ... I study, Pharmacyclics has initiated a broad Phase II ...
... 2011 This is a letter from Nicusa Capital urging BioClinica ... 2 and WITHHOLD votes from incumbent Directors Berg, Olukotun, Parker and ... Dr. David E. Nowicki Chairman of the Board BioClinica, Inc. 826 ... the Board of Directors of BioClinica: As of May ...
Cached Biology Technology:GeoVax Labs Announces Availability of 2010 Annual Report and President's Letter to Stockholders 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 9Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 10Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011 11This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Stanford, CA A startling discovery by scientists at ... arguably the most important biological process on Earth. Photosynthesis ... living things by producing food from sunlight, and in ... dioxide. But two studies by Arthur Grossman and colleagues*+ ...
... that leverages A-list female beauty to conserve the earths ... at upscale cosmetics counters around the world. The ... pleased to announce that Chantecaille, a luxury cosmetics company, ... gorgeous new Protected Paradise Face and Eyes compacts to ...
... BIO-key International,Inc. (OTC Bulletin Board: BKYI) today announced plans to ... March 17, 2008,after the market close. In conjunction with the ... live over the Internet,on Tuesday, March 18, 2008 at 9:00 ... Inc. Fourth Quarter and Full Year 2007 ...
Cached Biology News:New twist on life's power source 2New twist on life's power source 3Pew Institute teams with Chantecaille Cosmetics to protect global marine life 2BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule 2
... Opticon real-time PCR detection system uses a ... (450-495 nm) and a photomultiplier tube for ... is built on an DNA Engine thermal ... feature. This item includes the thermal cycler, ...
... Precision-designed for Optimal Microdissection , CapSure ... the precise and rapid extraction of populations ... cytology samples with Laser Capture Microdissection., ... Downstream Molecular Analysis , All CapSure LCM ...
... are highly sensitive laser confocal systems designed ... advanced scanners that meet your expectations, differentiating ... and optimizing the signal on the bottom ... the range for increased sensitivity. Results with ...
... four slides. The new ArraySlide 24-4 chamber ... x 7mm) individual printing surfaces for multiple ... studies. Unlike other systems, this device utilizes ... of contaminating adhesives. The chamber itself is ...
Biology Products: